SCHEDULE: FMR LLC Discloses 6.1% Stake in Insmed Inc.

FMR LLC, through its subsidiaries and affiliates, has reported beneficial ownership of 13,145,166.52 shares, representing 6.1% of the outstanding common stock of Insmed Inc. as of March 31, 2026.

Summary

• FMR LLC and its related entities, including Abigail P. Johnson, have filed a Schedule 13G indicating beneficial ownership of Insmed Inc. common stock.
• The filing reports a total of 13,145,166.52 shares owned, which constitutes 6.1% of the class of securities.
• This ownership level is as of March 31, 2026.
• FMR LLC is classified as an investment adviser (IA) and a holding company.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant stake by a major investor like FMR LLC can be positive, the Schedule 13G filing itself is a routine disclosure and does not provide performance data or strategic insights into Insmed Inc.

Positives

• FMR LLC, a significant investment management firm, has taken a notable stake in Insmed Inc., which could signal confidence in the company's prospects.
• The filing indicates FMR LLC has sole dispositive power over 13,145,166.52 shares, suggesting a clear investment strategy.

Risks

• The filing does not detail specific risks associated with Insmed Inc. itself, but any significant ownership by a large institutional investor can lead to increased scrutiny and potential activist investor involvement if performance falters.
• The concentration of voting power among the Johnson family within FMR LLC, as described in Exhibit 99, could lead to concentrated decision-making within FMR LLC's investment strategies.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Insmed Inc. regarding its future performance.

Management Comments

• FMR LLC and its subsidiaries, along with Abigail P. Johnson, are filing this Schedule 13G.
• Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.
• Members of the Johnson family are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
• The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major investment manager like FMR LLC, indicating a significant ownership stake (over 5%), often suggests a passive investment approach but can also precede more active engagement or signal strong conviction in the company's long-term value proposition within the biotechnology sector.

Stakeholder Impact

• Shareholders: The increased stake by a large institutional investor like FMR LLC may be viewed positively, potentially increasing investor confidence. However, it does not directly alter the company's operations or immediate financial standing.
• Management and Employees: No direct impact is indicated by this filing. The focus remains on Insmed Inc.'s operational performance.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Monitor future filings by FMR LLC and Insmed Inc. for any changes in ownership or strategic disclosures.
• Observe Insmed Inc.'s performance and strategic execution to understand the rationale behind FMR LLC's investment.

Key Dates

Recommendation

This Schedule 13G filing is a disclosure of beneficial ownership by FMR LLC and does not contain operational or financial performance data for Insmed Inc. Therefore, a 'hold' recommendation is appropriate as it reflects the need for further information and analysis of Insmed Inc.'s business before making a buy or sell decision.

Keywords

Insmed Inc., FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Abigail P. Johnson, Institutional Investor, SEC Filing